Insmed Reports Third Quarter 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Insmed (INSM) Misses Q3 EPS by 1c, Revenues Beat
October 30, 2019 7:39 AM EDTInsmed (NASDAQ: INSM) reported Q3 EPS of ($0.68), $0.01 worse than the analyst estimate of ($0.67). Revenue for the quarter came in at $38.9 million versus the consensus estimate of $35.89 million.
Third Quarter 2019 Financial Results
Total revenue for the third quarter ended September 30, 2019 was $38.9 million, comprising U.S. net sales of $37.8 million and ex-U.S. net sales of $1.1 million. The ex-U.S. net product sales include $0.9 million from the Temporary Authorization for Use (Autorisation Temporaire d\'Utilisation or ATU) program in France and $0.2 million from the named patient program in Germany, both compassionate use programs.Cost of... More